Evaluating the long-term benefits of hydroxyurea in pediatric sickle cell anemia
Abstract: Hydroxyurea is the primary disease-modifying medication for sickle cell anemia (SCA), but its long-term effects, particularly how these effects change over time, are not well understood. This study aimed to quantify the effects of hydroxyurea on clinical and laboratory outcomes in children...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2025-07-01
|
| Series: | Blood Advances |
| Acceso en liña: | http://www.sciencedirect.com/science/article/pii/S247395292500237X |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|